1. 43: NEOADJUVANT CHEMOTHERAPY OFFERS NO SURVIVAL BENEFIT FOR CT2N0M0 GASTRIC ADENOCARCINOMA. A MULTICENTRIC EUROPEAN STUDY. (23rd April 2022) Authors: Abboretti, F; Lambert, C; Schäfer, M; Le Roy, B; Mège, D; Demartines, N; Pezet, D; Gronnier, C; Mantziari, S Journal: Diseases of the esophagus Issue: Volume 35(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗